The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 13, 2023
Filed:
Nov. 25, 2020
Applicant:
Janssen Pharmaceutica NV, Beerse, BE;
Inventors:
Marc Mercken, Turnhout, BE;
Bianca Van Broeck, Schilde, BE;
Marc Vandermeeren, Geel, BE;
Bart Hermans, Beerse, BE;
Astrid Bottelbergs, Antwerp, BE;
Assignee:
Janssen Pharmaceutica NV, Beerse, BE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 49/00 (2006.01); A61K 49/16 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/18 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01); C07K 14/47 (2006.01); A61P 25/28 (2006.01); G01N 33/533 (2006.01); C12Q 1/37 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 39/3955 (2013.01); A61P 25/28 (2018.01); C07K 14/4711 (2013.01); G01N 33/6896 (2013.01); A01K 2267/0312 (2013.01); A61K 39/395 (2013.01); A61K 49/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12Q 1/37 (2013.01); G01N 33/533 (2013.01); G01N 2333/4709 (2013.01); G01N 2333/96425 (2013.01); G01N 2800/2814 (2013.01); G01N 2800/2821 (2013.01);
Abstract
The invention provides an antibody or antigen binding fragments thereof that binds to 3pE Aβ and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other β-amyloid-related diseases.